Showing 281-290 of 1560 results for "".
Beyond BCVA: Measuring Functional Vision in MacTel Type 2
https://reachmd.com/programs/cme/Beyond-BCVA-Measuring-Functional-Vision-in-MacTel-Type-2/35965/Catch up on the latest information on the management of macular telangiectasia type 2 (MacTel) with a new encapsulated cell therapy, revakinagene taroretcel.The Evolving gMG Treatment Landscape
https://reachmd.com/programs/neurofrontiers/the-evolving-gmg-treatment-landscape/30070/The newest findings on generalized myasthenia gravis treatment include FcRn inhibitors and B-cell targeting. Catch up now.Applying Perioperative ICIs in Clinical Practice
https://reachmd.com/programs/cme/applying-perioperative-icis-in-clinical-practice/36634/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Managing Immune-Related Adverse Events in the Perioperative Setting
https://reachmd.com/programs/cme/managing-immune-related-adverse-events-in-the-perioperative-setting/36635/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Rationale for Combining Radiation and Immunotherapy in Resectable Locally Advanced HNSCC
https://reachmd.com/programs/cme/rationale-for-combining-radiation-and-immunotherapy-in-resectable-locally-advanced-hnscc/36592/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Risk Stratification and Patient Selection for Perioperative ICIs
https://reachmd.com/programs/cme/risk-stratification-and-patient-selection-for-perioperative-icis/36633/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Emerging Evidence for Perioperative ICIs in Locally Advanced HNSCC
https://reachmd.com/programs/cme/emerging-evidence-for-perioperative-icis-in-locally-advanced-hnscc/36593/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.The Evolving Landscape of Resectable Locally Advanced HNSCC
https://reachmd.com/programs/cme/the-evolving-landscape-of-resectable-locally-advanced-hnscc/36576/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.Multidisciplinary Collaboration Facilitates Multimodality Therapy
https://reachmd.com/programs/cme/multidisciplinary-collaboration-facilitates-multimodality-therapy/36636/Explore perioperative immunotherapy and multimodal strategies to optimize patient outcomes in resectable locally advanced head and neck squamous cell carcinoma.New Experimental Treatments for Diabetic Wounds
https://reachmd.com/programs/diabetes-discourse/new-experimental-treatments-for-diabetic-wounds/6388/Experimental approaches, including the suppression of certain immune cells to speed difficult wounds, may lead healthcare professionals to advances in the treatment of diabetic wounds. What are the therapeutic strategies and implications for our patients with diabetes? Join guest host Dr. Timothy Ba